Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A new vision to accelerate the search for an HIV vaccine, developed by the Council of the Global HIV Vaccine Enterprise with the participation of hundreds of scientists, policy makers, funders, and advocates worldwide, was published today in Nature Medicine.
The Scientific Strategic Plan of the Global HIV Vaccine Enterprise provides a forward-looking framework to speed the development, execution, and analysis of HIV vaccine trials; better integrate preclinical and clinical research; more effectively capitalize on scientific advances from other fields; and bring new researchers and new funders to the global effort to develop a safe and effective HIV vaccine.
The plan, the product of an 18-month collaborative process involving input from more than 400 researchers, policy makers, funders,and advocates worldwide, was developed by the Global HIV Vaccine Enterprise, an alliance of independent HIV vaccine research funding, policy, and advocacy organizations dedicated to accelerating the development of a preventive HIV vaccine.
The strategy released today is a full update of a Scientific Strategic Plan developed in 2005. That plan substantially reshaped the field, leading to the creation of new initiatives to address longstanding scientific and organizational obstacles in HIV vaccine research, and helping to promote many of the scientific advances that have brought the goal of a safe and effective HIV vaccine closer today.
The new Scientific Strategic Plan seeks to build rapidly on recent progress in the field by tackling the most significant barriers to HIV vaccine research. The plan is informed by detailed reports on specific challenges and opportunities in the field developed by five Working Groups created by the Enterprise Science Committee.
"We are at an important moment in the 27-year journey to develop an effective vaccine against HIV," said Alan Bernstein, Ph.D., executive director of the Global HIV Vaccine Enterprise. "Last year, the RV144 trial in Thailand provided the first evidence that a vaccine can prevent HIV acquisition. Recent discoveries such as the isolation of broadly neutralizing antibodies are informing new strategies for vaccine design, while powerful new technologies are significantly advancing our understanding of HIV infection and the human immune system. These scientific advances, coupled with a new spirit of global collaboration in HIV vaccine research and the ambitious roadmap provided by the Scientific Strategic Plan of the Enterprise, point to a new era of great progress in the search for an HIV vaccine."
"HIV/AIDS is a catastrophic global epidemic, and a vaccine is a top global health priority," said Peter Piot, MD, Ph.D., incoming director of the London School of Hygiene and Tropical Medicine and chair of the Global HIV Vaccine Enterprise. "With 33 million people living with HIV, 50,000 new infections each week and only two in five people in need receiving HIV treatment, the need for a vaccine that can help slow and one day end this epidemic has never been greater."
"There has been notable progress in the quest to identify an effective HIV vaccine. The new Enterprise Scientific Strategic Plan will further catalyze the collaborative research necessary to build on recent advances and bring a safe and effective HIV vaccine closer to reality," said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health.
The Scientific Strategic Plan provides a set of priorities and recommendations to build on the progress of the last five years. The Plan highlights the need to fundamentally alter how clinical trials are developed and implemented and recommends that the field:
>strengthen existing research structures or create new ones that bring together basic, preclinical and clinical researchers to design, execute and analyze trials;
>explore novel trial design strategies and implement process improvements to significantly increase the number, efficiency and speed of clinical trials;
>develop a robust pipeline of diverse vaccine strategies;
>ensure the compatibility of trial data, regardless of sponsor;
>strengthen the global, ethical, legal and regulatory frameworks that guide and facilitate HIV vaccine research;
>maintain appropriate and flexible research capacity in high-incidence countries; and
>strengthen community engagement throughout trial design and implementation.
The plan also recommends a series of strategies to harness the full potential of significant recent advances in biomedical science through greater efforts to incorporate new tools and ideas from other areas of biomedical research. Among these are advanced imaging technologies to study mucosal immunity and genomic technologies to better understand host factors that regulate the immune response. The Plan calls for increased efforts to foster collaboration with researchers from disciplines that have the potential to transform current approaches to HIV vaccine discovery and development, such as systems biology, which provides a promising approach for the integrative analysis and modeling of large datasets.
The Scientific Strategic Plan also includes recommendations to:
>increase the engagement of the pharmaceutical and biotechnology industries in advancing vaccine research and development;
>strategies to attract and support the brightest minds to HIV vaccine research, including efforts to mentor young and early-career investigators from regions seriously affected by the epidemic;
>expand and diversify funding for HIV vaccine research. Currently, the vast majority of global HIV vaccine research support is provided by a handful of funders, with many wealthy nations and emerging economies and technological powers contributing little to the global effort.
"We need a rich diversity of global support in order to successfully develop an HIV vaccine and start writing the story of the end of AIDS," said Jose Esparza, senior adviser for HIV vaccines at the Bill & Melinda Gates Foundation. "From funding to building and supporting national research systems, many more countries and funders must become fully engaged in this effort."
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Plus: Featured Video
Latest Stories
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM